Glenmark launches Clobetasol Propionate dermatology products

MUMBAI, India Glenmark Pharmaceuticals has begun marketing and distributing five Clobetasol Propionate dermatology products, according to published reports.

Glenmark acquired the rights for the drugs from a pharmaceutical development company. The types of Clobetasol included in the deal were: a cream, E cream, ointment, gel and topical solution.

Clobetasol Propionate is used to treat diseases such as eczema and psoriasis, where it is used on the scalp and body. It is also dispensed to counter autoimmune presentations, such as hair loss and skin nodules. The total sales for the Clobetasol Propionate products in the 12-month period ending December 2007 were in excess of $28 million, according to IMS Health.

This acquisition marks Glenmark’s introduction into the U.S. semisolid business. The company plans on launching an additional 11 dermatological products in the U.S. in the next year.